Acute myeloid leukemia patients' clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts

Haematologica. 2016 May;101(5):e185-8. doi: 10.3324/haematol.2015.139717. Epub 2016 Feb 11.

¹ Roche Innovation Center Basel, Roche Pharma Research and Early Development, Switzerland.
² Roche Innovation Center New York, Roche Pharma Research and Early Development, NY, USA.
³ Seragnoli Institute of Hematology, Bologna University School of Medicine, Italy.
⁴ Department of Haematology, Peter MacCallum Cancer Center, Melbourne, VIC, Australia.
⁵ Beatson West of Scotland Cancer Center, Gartnavel General Hospital, Glasgow, United Kingdom.
⁶ Division of Hematology, Jewish General Hospital, McGill University, Montreal, QC, Canada.
⁷ Department of Hematology, Asian Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
⁸ Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.
⁹ Department of Internal Medicine, Seoul National University School of Medicine, Seoul, South Korea.
¹⁰ Roche Innovation Center Penzberg, Roche Pharma Research and Early Development, Germany.
¹¹ New York Medical College, Valhalla, NY, USA.
¹² University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
¹³ Hematology, Institut Paoli Calmettes, Marseilles, France.
¹⁴ Princess Margaret Hospital, Toronto, ON, Canada.
¹⁵ Roche Innovation Center New York, Roche Pharma Research and Early Development, NY, USA [email protected].

No abstract available

Keywords: AML; MDM2 antagonism; complementary diagnostics; flow cytometry; idasanutlin.

Publication types